Carley Legan
Internal Medicine · Richardson, TXNPI 1780030999
Payments from drug & device makers
Across 206 payments — averaging $18.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$840
- Pfizer$347
- AstraZeneca$297
- Otsuka America Pharmaceutical, Inc.$294
- AbbVie$246
- Novo Nordisk$241
- plus $2K from 22 others
What the payments were for
- Food & beverage$3,766100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 44 | $840 |
| Pfizer | 19 | $347 |
| AstraZeneca | 17 | $297 |
| Otsuka America Pharmaceutical, Inc. | 14 | $294 |
| AbbVie | 20 | $246 |
| Novo Nordisk | 17 | $241 |
| Lilly USA, LLC | 12 | $192 |
| Corcept Therapeutics | 6 | $143 |
| Eisai Inc. | 5 | $133 |
| Dexcom, Inc. | 5 | $108 |
| Axsome Therapeutics, Inc. | 4 | $105 |
| Bayer | 5 | $97 |
| Merck | 4 | $95 |
| GSK | 6 | $89 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $85 |
| E.r. Squibb & Sons, L.L.C. | 4 | $81 |
| Exact Sciences | 4 | $74 |
| Boehringer Ingelheim | 2 | $42 |
| Sumitomo Pharma America, Inc. | 2 | $39 |
| Novartis | 2 | $36 |
| Idorsia Pharmaceuticals US Inc | 2 | $36 |
| Amgen | 2 | $34 |
| Abbott | 1 | $24 |
| Exeltis, USA Inc. | 1 | $24 |
| Renalytix AI, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Phadia US Inc. | 1 | $14 |
How this compares
$3,766 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 11 | $272 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 18 | $176 |
| Atorvastatin Calcium | 27 | $159 |
| Amlodipine Besylate | 13 | $124 |
| Methocarbamol | 14 | $90 |
| Furosemide | 13 | $79 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $77 |
| Levothyroxine Sodium | 12 | $40 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Richardson
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.